close
close

US Penny Stocks to Watch in November 2024

As the U.S. stock market hits record highs, fueled by a post-election rebound and optimism about interest rate cuts, investors are exploring various ways to capitalize on this momentum. Although penny stocks are often overlooked and viewed as a relic of bygone market days, they remain an interesting investment area for those seeking potential growth in smaller or lesser-known companies. By focusing on penny stocks with strong financial health and clear growth paths, investors could discover promising opportunities that align with today’s dynamic market conditions.

name

Share price

Market capitalization

Financial health assessment

BAB (OTCPK:BABB)

$0.78

$5.56 million

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$170.72 million

★★★★★★

Flexible Solutions International (NYSEAM:FSI)

$4.37

$51.05 million

★★★★★★

RLX Technology (NYSE:RLX)

$1.60

$2.07 billion

★★★★★★

AsiaFIN Holdings (OTCPK:ASFH)

$0.97

$79.11 million

★★★★★★

PHX Minerals (NYSE:PHX)

$3.35

$128.93 million

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$88.26 million

★★★★☆☆

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71 million

★★★★★★

Puma Biotechnology (NasdaqGS:PBYI)

$3.30

$141.37 million

★★★★★★

CBAK Energy Technology (NasdaqCM:CBAT)

$1,015

$96.23 million

★★★★★☆

Click here to see the full list of 738 stocks from our US Penny Stocks Screener.

We’ll look at some of the best tips from our screener tool.

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Bitcoin Depot Inc. operates a network of cryptocurrency kiosks across North America and has a market capitalization of $102.86 million.

Operations: The company’s revenue comes primarily from the data processing segment and totals $629.50 million.

Market capitalization: $102.86 million

Bitcoin Depot Inc. operates in the volatile penny stock space with a market cap of $102.86 million and has shown mixed financial performance. Despite being unprofitable, the company reported net income of $11.26 million for the second quarter of 2024, recouping a loss from the previous year. The company’s current assets exceed both its short-term and long-term liabilities, indicating sound liquidity management. However, there has been shareholder dilution over the past year and the share price remains extremely volatile. Recent strategic moves include pursuing M&A opportunities and switching auditors to Wolf & Company amid delayed SEC filings.

Breakdown of NasdaqCM:BTM’s income and expenses as of November 2024

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Taysha Gene Therapies, Inc. is a gene therapy company developing and commercializing adeno-associated virus-based treatments for monogenic diseases of the central nervous system, with a market capitalization of $307.41 million.

You may also like...